Read Summary

Long-term results from the Dutch PREOPANC trial confirm that neoadjuvant chemoradiotherapy conveys a survival advantage to patients with resectable and borderline resectable pancreatic cancer.
Medscape Medical News

Print Friendly, PDF & Email